TickerStat.comEloxx Pharmaceuticals annual working capital
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Eloxx Pharmaceuticals Working Capital Growth & History (ELOX)
Eloxx Pharmaceuticals's working capital was −$11.9M for fiscal 2025.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual working capital history
| Fiscal year | Period ended | Working capital | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$11.9M | $12.4M | — |
| 2024 | 2024-12-31 | −$24.3M | −$3.2M | — |
| 2023 | 2023-12-31 | −$21.1M | −$18.2M | — |
| 2022 | 2022-12-31 | −$3.0M | −$36.5M | — |
| 2021 | 2021-12-31 | $33.5M | $17.5M | +108.81% |
| 2020 | 2020-12-31 | $16.1M | −$29.8M | −65.02% |
| 2019 | 2019-12-31 | $45.9M | $3.4M | +7.92% |
| 2018 | 2018-12-31 | $42.5M | $21.5M | +101.75% |
| 2017 · Dec 31 | 2017-12-31 | $21.1M | $20.5M | +3605.27% |
| 2017 · Jun 30 | 2017-06-30 | −$2.5M | −$3.1M | — |
| 2016 · Dec 31 | 2016-12-31 | $569,000 | −$1.5M | −73.14% |
| 2016 · Jun 30 | 2016-06-30 | $613,637 | −$2.3M | −79.21% |
| 2015 · Dec 31 | 2015-12-31 | $2.1M | — | — |
| 2015 · Jun 30 | 2015-06-30 | $3.0M | −$2.4M | −45.34% |
| 2014 | 2014-06-30 | $5.4M | $5.1M | +1644.09% |
| 2013 | 2013-06-30 | $309,572 | −$76,960 | −19.91% |
| 2012 | 2012-06-30 | $386,532 | −$1.4M | −78.38% |
| 2011 | 2011-06-30 | $1.8M | — | — |
Eloxx Pharmaceuticals quarterly working capital
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q4.16
Q1.17
Q4.16
Q1.17
Q4.17
Q1.18
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q4.24
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Working capital | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $46.4M | — | — |
| Q1 2026 | 2026-03-31 | −$7.6M | — | — |
| Q4 2025 | 2025-12-31 | −$11.9M | $12.4M | — |
| Q4 2024 | 2024-12-31 | −$24.3M | −$3.2M | — |
| Q4 2023 | 2023-12-31 | −$21.1M | −$18.2M | — |
| Q3 2023 | 2023-09-30 | −$17.8M | −$21.8M | — |
| Q2 2023 | 2023-06-30 | −$15.9M | −$28.0M | — |
| Q1 2023 | 2023-03-31 | −$13.1M | −$36.0M | — |
| Q4 2022 | 2022-12-31 | −$3.0M | −$36.5M | — |
| Q3 2022 | 2022-09-30 | $4.0M | −$40.0M | −90.94% |
| Q2 2022 | 2022-06-30 | $12.1M | −$31.3M | −72.11% |
| Q1 2022 | 2022-03-31 | $23.0M | $15.7M | +216.13% |
| Q4 2021 | 2021-12-31 | $33.5M | $17.5M | +108.81% |
| Q3 2021 | 2021-09-30 | $44.0M | $21.8M | +98.10% |
| Q2 2021 | 2021-06-30 | $43.3M | $15.2M | +53.74% |
| Q1 2021 | 2021-03-31 | $7.3M | −$27.6M | −79.14% |
| Q4 2020 | 2020-12-31 | $16.1M | −$29.8M | −65.02% |
| Q3 2020 | 2020-09-30 | $22.2M | −$33.4M | −60.04% |
| Q2 2020 | 2020-06-30 | $28.2M | −$38.5M | −57.75% |
| Q1 2020 | 2020-03-31 | $34.8M | −$12.2M | −25.92% |
| Q4 2019 | 2019-12-31 | $45.9M | $3.4M | +7.92% |
| Q3 2019 | 2019-09-30 | $55.6M | $4.6M | +8.95% |
| Q2 2019 | 2019-06-30 | $66.7M | $7.1M | +11.96% |
| Q1 2019 | 2019-03-31 | $47.0M | $33.8M | +256.60% |
| Q4 2018 | 2018-12-31 | $42.5M | $21.5M | +101.75% |
| Q3 2018 | 2018-09-30 | $51.1M | $51.1M | — |
| Q2 2018 | 2018-06-30 | $59.6M | $62.1M | — |
| Q1 2018 · Mar 31 | 2018-03-31 | $13.2M | $14.0M | — |
| Q4 2017 · Dec 31 | 2017-12-31 | $21.1M | $20.5M | +3605.27% |
| Q1 2018 · Sep 30 | 2017-09-30 | −$37,833 | $53,526 | — |
| Q4 2017 · Jun 30 | 2017-06-30 | −$2.5M | −$3.1M | — |
| Q1 2017 · Mar 31 | 2017-03-31 | −$785,215 | −$2.0M | — |
| Q4 2016 · Dec 31 | 2016-12-31 | $569,000 | −$1.5M | −73.14% |
| Q1 2017 · Sep 30 | 2016-09-30 | −$91,359 | −$3.1M | — |
| Q4 2016 · Jun 30 | 2016-06-30 | $613,637 | −$2.3M | −79.21% |
| Q1 2016 · Mar 31 | 2016-03-31 | $1.2M | $2.3M | — |
| Q4 2015 · Dec 31 | 2015-12-31 | $2.1M | $2.3M | — |
| Q1 2016 · Sep 30 | 2015-09-30 | $3.0M | $622,432 | +26.42% |
| Q4 2015 · Jun 30 | 2015-06-30 | $3.0M | −$2.4M | −45.34% |
| Q3 2015 | 2015-03-31 | −$1.1M | −$7.4M | — |
| Q2 2015 | 2014-12-31 | −$175,444 | −$4.5M | — |
| Q1 2015 | 2014-09-30 | $2.4M | $3.6M | — |
| Q4 2014 | 2014-06-30 | $5.4M | $5.1M | +1644.09% |
| Q3 2014 | 2014-03-31 | $6.3M | $6.3M | +8365.57% |
| Q2 2014 | 2013-12-31 | $4.3M | $6.1M | — |
| Q1 2014 | 2013-09-30 | −$1.2M | −$577,432 | — |
| Q4 2013 | 2013-06-30 | $309,572 | −$76,960 | −19.91% |
| Q3 2013 | 2013-03-31 | $74,922 | −$1.3M | −94.69% |
| Q2 2013 | 2012-12-31 | −$1.8M | −$1.6M | — |
| Q1 2013 | 2012-09-30 | −$664,562 | −$1.5M | — |
| Q4 2012 | 2012-06-30 | $386,532 | −$1.4M | −78.38% |
| Q3 2012 | 2012-03-31 | $1.4M | — | — |
| Q2 2012 | 2011-12-31 | −$235,129 | — | — |
| Q1 2012 | 2011-09-30 | $867,210 | — | — |
| Q4 2011 | 2011-06-30 | $1.8M | — | — |
Eloxx Pharmaceuticals working capital trends
Over the last five fiscal years, Eloxx Pharmaceuticals's working capital decreased from $16.1M to −$11.9M, a change of −$28.0M. The latest reported quarter, Q2 2026, shows $46.4M.
About the metric
What working capital means
Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.
Calculation and source
How working capital is calculated
TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...